Martin Stumpe, PhD, Chief Data & Artificial Intelligence Officer at Danaher, examines the factors affecting AI’s impact on drug discovery. The artificial intelligence (AI) boom in life sciences has sparked a rush of new technologies to design molecules fit for purpose. The potential is enormous, with promised benefits for both therapeutics and manufacturing. The number […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!